Xbrane Biopharma Financials
| XBRANE Stock | SEK 0.25 0.03 10.71% |
Xbrane |
Understanding current and past Xbrane Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Xbrane Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Xbrane Biopharma's assets may result in an increase in income on the income statement.
Please note, the presentation of Xbrane Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Xbrane Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Xbrane Biopharma's management manipulating its earnings.
Xbrane Biopharma Stock Summary
Xbrane Biopharma competes with Hansa Biopharma, Vicore Pharma, XSpray Pharma, and Saniona AB. Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 35 people.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0007789409 |
| Business Address | Retzius vg 8, |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.xbrane.com |
| Phone | 46 7 60 34 67 33 |
| Currency | SEK - Swedish Kronor |
You should never invest in Xbrane Biopharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Xbrane Stock, because this is throwing your money away. Analyzing the key information contained in Xbrane Biopharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Xbrane Biopharma Key Financial Ratios
Xbrane Biopharma's financial ratios allow both analysts and investors to convert raw data from Xbrane Biopharma's financial statements into concise, actionable information that can be used to evaluate the performance of Xbrane Biopharma over time and compare it to other companies across industries.| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 | |||
| Target Price | 136.5 | |||
| Number Of Employees | 74 | |||
| Beta | 1.37 |
Xbrane Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Xbrane Biopharma's current stock value. Our valuation model uses many indicators to compare Xbrane Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xbrane Biopharma competition to find correlations between indicators driving Xbrane Biopharma's intrinsic value. More Info.Xbrane Biopharma AB is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Xbrane Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Xbrane Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Xbrane Biopharma Systematic Risk
Xbrane Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Xbrane Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Xbrane Biopharma correlated with the market. If Beta is less than 0 Xbrane Biopharma generally moves in the opposite direction as compared to the market. If Xbrane Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Xbrane Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Xbrane Biopharma is generally in the same direction as the market. If Beta > 1 Xbrane Biopharma moves generally in the same direction as, but more than the movement of the benchmark.
Xbrane Biopharma March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Xbrane Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Xbrane Biopharma AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Xbrane Biopharma AB based on widely used predictive technical indicators. In general, we focus on analyzing Xbrane Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Xbrane Biopharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 6.81 | |||
| Information Ratio | 0.131 | |||
| Maximum Drawdown | 40.0 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 7.14 |
Complementary Tools for Xbrane Stock analysis
When running Xbrane Biopharma's price analysis, check to measure Xbrane Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xbrane Biopharma is operating at the current time. Most of Xbrane Biopharma's value examination focuses on studying past and present price action to predict the probability of Xbrane Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xbrane Biopharma's price. Additionally, you may evaluate how the addition of Xbrane Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |